MMIT and Evaluate Join Forces to Offer an End-to-End View of the Pharmaceutical Market Landscape
London, UK and Yardley, Pennsylvania.-based Managed Markets Insight & Technology (MMIT), LLC, the trusted go-to-market partner solely focused on solving the “what and why” of market access, has joined forces with London-based Evaluate, a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry. This newly merged organization will offer customers a unique and comprehensive data solution offering both analytical and predictive data insights across the entire drug life cycle.
“MMIT and Evaluate share a mission of helping patients get access to lifesaving therapies,” said Mike Gallup, CEO of MMIT. “As customers’ decision-making processes become increasingly more centralized, we couldn’t be more thrilled to come together and offer a comprehensive solution for bringing new drugs to market and to patients.”
The two organizations will become a leading pharma commercial intelligence provider—one that aims to inform and support customers from pipeline to prescription. Combining Evaluate’s data-driven understanding of commercial opportunities with MMIT’s insight into patient coverage will offer customers an end-to-end view of the pharmaceutical market landscape, allowing them to enhance high-value strategic portfolio decisions, assess unmet needs, evaluate barriers to access, and develop pricing strategies and value propositions to ensure that treatments get in the hands of patients.
“It’s an exciting time for our new combined organization,” said Evaluate CEO Deborah Kobewka. “Evaluate and MMIT have a shared vision to enhance patient outcomes by helping them access innovative treatments faster. Together, we are better placed to help our customers identify and evaluate strategic, valuable R&D investments and smooth access to therapies for those who need it the most—the patients.”
Deborah Kobewka will continue in her role as Evaluate’s CEO, while MMIT’s CEO, Mike Gallup, will be CEO of the combined entity. Upon completion of the merger, MMIT’s equity partner, Welsh, Carson, Anderson & Stowe (WCAS), and Evaluate’s equity partner, Hg, will share joint control of the combined business.
“There are enormous growth opportunities ahead for this combined business with over 1,300 global customers, highly complementary solutions and differentiated offerings in the market. We are delighted to continue partnering with the management team at MMIT while welcoming the team from Evaluate and our new partner, Hg,” said Ed Sobol, general partner at WCAS.
“This combination brings together two high-quality businesses and teams to form a new global player in commercial pharma intelligence, delivering better outcomes to the entire healthcare ecosystem and helping patients access treatments more efficiently,” said David Issott, partner at Hg. “We’re proud of what we’ve achieved alongside the Evaluate team to date and are excited to partner with WCAS and MMIT in supporting the accelerated growth of this new combined business.”
The terms of the transaction have not been disclosed and completion is subject to customary closing conditions.
About MMIT
For nearly two decades, MMIT has been solely focused on solving the “what and why” of market access, and has been a trusted, go-to-market partner. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions.
Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit, and The Dedham Group, the preeminent U.S. market access oncology and specialty therapeutics consultancy. For more information about MMIT, visit mmitnetwork.com and follow us on LinkedIn.
About Evaluate
Since 1996, Evaluate has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary & industry data into their workflows, tools and processes so they can work more effectively and efficiently. For more information about Evaluate, visit www.evaluate.com and follow us on LinkedIn.
About Welsh, Carson, Anderson & Stowe
WCAS is a leading U.S. private equity firm focused on two target industries: healthcare and technology. Since its founding in 1979, the Firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. WCAS has raised and managed funds totalling over $27 billion of committed capital. For more information, please visit www.wcas.com
About Hg
Hg is a leading investor in software and services, focused on backing businesses that change how we all do business. Deep technology expertise, complemented by vertical application specialisation and dedicated operational support, provides a compelling proposition to management teams looking to scale their businesses. Hg has funds under management of over $37 billion, with an investment team of over 140 professionals, plus a portfolio team of more than 35 operators, providing practical support to help our businesses to realise their growth ambitions. Based in London, Munich and New York, Hg has a portfolio of over 35 software and technology businesses, worth around $70 billion aggregate enterprise value, with over 50,000 employees globally, growing at over 20% per year. Visit www.hgcapital.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005226/en/
Contact information
Katleen Richardson
Senior Vice President Marketing
marketing@evaluate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 11:53:00 EET | Press release
Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where high-quality assets can be tightly held. The Fund holds positions in the 2nd and 3rd largest commercial timberlands estates in New Zealand, one of Australia’s largest softwood forest
Smartstream Introduces Agentic AI ‘Smart Agents’ for Investigations and Exceptions Handling4.12.2025 10:55:00 EET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the preview of Smart Agents for Investigations, a breakthrough in financial operations that brings augmented and autonomous exception handling to reconciliations and back-office processes. The new investigation agent combines domain-trained AI agents, workflow adoption, and embedded controls to triage, investigate, resolve, and learn from exceptions - reducing manual effort, accelerating time to resolution, and strengthening auditability. It will add a layer of intelligence on top of Smartstream’s current reconciliations and exceptions solutions. It understands the breaks context, adheres to customer playbooks and reaches out for missing information. It documents every step for audit and compliance, allowing analysts to focus on risk. Finally, it augments the analyst’s investigation with contextual information radically changing the user experience to review and a
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes4.12.2025 10:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA™ platform to optimise NANOBODY® molecules for multiple new targets in the area of inflammation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204759388/en/ “We are truly excited about this new collaboration with Sanofi,”said LabGenius’ CSO, Dr. Angus Sinclair. “This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across
GoWit One: The Unified AI Operating System Set to Revolutionize Commerce & Retail Media4.12.2025 08:09:00 EET | Press release
GoWit, a global AdTech leader in omnichannel Commerce and Retail Media, announced the launch of GoWit One, the unified AI operating system that brings automation, unification, and real-time intelligence into a single ad platform for agencies operating across multiple retailers, channels, and markets. By bringing these three elements into one dashboard, GoWit One addresses the industry's most critical bottleneck: operational inefficiency. The platform enables agencies to manage campaigns across multiple retailers, channels, and markets, reducing manual AdOps workflows by 98%, turning a process that used to take hours into as little as 10 minutes. Solving the “Fragmentation Crisis” Despite the explosive growth of Retail Media, the industry faces a significant hurdle. According to the IAB, 70% of the market still lacks end-to-end AI adoption. Media buyers are currently forced to juggle disconnected networks, compliance rules, and dashboards, leading to manual errors and an inability to sc
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings4.12.2025 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation. S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow. The agency also notes Galderma’s disciplined financial policy, supporting expectations of continued deleveraging over the coming years. The positive outlook indicates that an upgrade could be considered over the next 12–24 months subject to Galderma continuing to deliver profitable g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom